

- Both dimethylsulfoxide (DMSO) and povidone iodine (PVP-I) have been known separately in the medical and pharmaceutical literature for decades.
- No one had previously contemplated their combined use in ophthalmic formulations until the current report.
- We have shown possible success with this novel formulation of low-dose PVP-I in a proprietary DMSO gel/solvent system for a difficult case of rosacea blepharoconjunctivitis.
- This novel therapy may warrant further investigation in randomized, controlled clinical trials.

This summary slide represents the opinions of the authors. The article processing charges for this publication were funded by ALC Therapeutics, LLC, Springhouse, PA, USA. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).